文献速递慢阻肺

泰国慢性阻塞性肺疾病单吸入器三联疗法的经济学评价

Economic evaluation of single-inhaler triple therapy for chronic obstructive pulmonary disease in Thailand
RSS 订阅 · BMJ Open Respiratory Research

本研究采用终身视野的马尔可夫模型,从社会角度比较两种单吸入器三联疗法(SITT)与多吸入器三联疗法(MITT)治疗泰国COPD的成本-效用。结果显示,与SAL/FP+TIO相比,FF/UMEC/VI可提高QALY 0.014但增加终身成本25,649泰铢,ICER为1,899,408泰铢/QALY;BUD/GLY/FOR的QALY更低(-0.007)且成本更高,被SAL/FP+TIO支配。概率敏感性分析显示FF/UMEC/VI在160,000泰铢阈值下具有成本效果的概率仅为1.1%。结论认为当前价格下SITT不具有成本效果,但FF/UMEC/VI降价约30%后可能成为有前景的选择。

要点

  • 与SAL/FP+TIO相比,FF/UMEC/VI提高QALY 0.014,ICER为1,899,408泰铢/QALY。
  • BUD/GLY/FOR的QALY较SAL/FP+TIO低0.007且成本更高,被SAL/FP+TIO支配。
  • FF/UMEC/VI在160,000泰铢阈值下具有成本效果的概率为1.1%,降价30%可成为有成本效果的选择。

核心结论

  • 当前价格下,与现行MITT相比,SITT治疗COPD不具有成本效果;FF/UMEC/VI在降价约30%后可能成为有前景的选择。

研究设计与样本

  • 采用终身视野、社会角度的马尔可夫模型,包含7个健康状态:中度、重度、极重度(各含急性加重与不含急性加重)及死亡。
  • 比较两种SITT(FF/UMEC/VI和BUD/GLY/FOR)与MITT(SAL/FP+TIO),通过全面文献综述确定模型输入,计算QALY和ICER,并进行系列敏感性分析。

主要发现

  • 与SAL/FP+TIO相比,FF/UMEC/VI提高QALY 0.014,终身成本增加25,649泰铢(727美元)。
  • 与SAL/FP+TIO相比,BUD/GLY/FOR的QALY低0.007,终身总成本增加34,151泰铢(968美元)。
  • FF/UMEC/VI的ICER为1,899,408泰铢/QALY(53,823美元),BUD/GLY/FOR被SAL/FP+TIO支配。
  • 概率敏感性分析显示,在160,000泰铢(4,533美元)阈值下,FF/UMEC/VI具有成本效果的概率为1.1%。
  • FF/UMEC/VI价格降低30%可使其成为有成本效果的选择。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Introduction Single-inhaler triple therapy (SITT) is known to be a cost-effective intervention for chronic obstructive pulmonary disease (COPD) in Western countries, but there is no such evidence for resource-limited countries. This study aimed to evaluate the cost-utility of SITT compared with multiple inhaler triple therapy (MITT) for COPD in Thailand. Methods A Markov model with a lifetime horizon from a societal perspective was conducted with seven health states, including moderate, severe and very severe, with and without acute exacerbation (AE) and death. Two SITTs, fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) and budesonide/glycopyrrolate/formoterol (BUD/GLY/FOR), were compared with MITT (salmeterol/fluticasone propionate with tiotropium (SAL/FP+TIO). A comprehensive literature review was performed to identify inputs. A quality-adjusted life year (QALY) and incremental cost-effectiveness ratio (ICER) were calculated. A series of sensitivity analyses was performed. Results FF/UMEC/VI could improve QALY by 0.014 with an increased lifetime cost of 25 649 Thai baht (THB) ($727) compared with SAL/FP+TIO. In contrast, BUD/GLY/FOR had a lower QALY of –0.007 with an increased total lifetime cost of 34,151 THB ($968). The ICER for FF/UMEC/VI was 1,899,408 THB/QALY ($53,823), while BUD/GLY/FOR was dominated by SAL/FP+TIO. Probabilistic sensitivity analysis indicated that FF/UMEC/VI had a 1.1% chance of being cost-effective at the threshold of 160,000 THB ($4,533). We found that a 30% reduction in FF/UMEC/VI price could lead to a cost-effective option. Conclusion Our study indicated that SITTs are not cost-effective at the current price compared with the current MITT for COPD treatment. However, FF/UMEC/VI could be a promising option, with an approximately 30% price reduction.

来源:BMJ Open Respiratory Research,查看原文。版权归原作者所有。

引用

  1. BMJ Open Respiratory Research:Economic evaluation of single-inhaler triple therapy for chronic obstructive pulmonary disease in Thailand

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。